Hologic, Inc. (NASDAQ:HOLX) Short Interest Update

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 7,260,000 shares, an increase of 35.7% from the April 30th total of 5,350,000 shares. Based on an average daily volume of 3,380,000 shares, the short-interest ratio is presently 2.1 days. Currently, 3.3% of the company's shares are short sold.

Hologic Stock Performance

Shares of HOLX traded up $1.26 during trading hours on Friday, reaching $64.33. 2,266,870 shares of the company traded hands, compared to its average volume of 2,287,561. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average price of $58.21 and a 200-day moving average price of $65.54. Hologic has a 12-month low of $51.90 and a 12-month high of $84.67. The stock has a market capitalization of $14.34 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the business earned $1.03 EPS. The company's quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts anticipate that Hologic will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the company's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by corporate insiders.

Institutional Trading of Hologic

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. Venturi Wealth Management LLC raised its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Hologic in the 1st quarter valued at about $34,000. Allworth Financial LP lifted its holdings in shares of Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Hologic during the first quarter worth about $42,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on HOLX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Morgan Stanley cut their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Raymond James reiterated an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Finally, Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.